Trials / Completed
CompletedNCT02609165
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Ospedale San Raffaele · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at investigating the therapeutic potential of recombinant human Nerve Growth Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhNGF 180 µg/ml eye drops solution | eye drops |
| DRUG | vehicle eye drops | placebo |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2015-11-20
- Last updated
- 2017-09-06
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02609165. Inclusion in this directory is not an endorsement.